Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$436.30 USD

436.30
365,572

+3.87 (0.89%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $436.55 +0.25 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds

by Zacks Equity Research

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

Zacks Equity Research

QIAGEN (QGEN) Expands in NGS and FIGG With New Partnership

by Zacks Equity Research

QIAGEN (QGEN) announces a collaboration with the Snow Molecular Anthropology Lab at the University of Montana to enhance the identification of human remains of Indigenous people and African Americans.

Zacks Equity Research

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

by Zacks Equity Research

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

Zacks Equity Research

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

by Zacks Equity Research

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

Zacks Equity Research

Valneva (VALN) Gets EC's Approval on Chikungunya Vaccine

by Zacks Equity Research

Valneva (VALN) gets European Commission???s marketing authorization in Europe for Valneva???s single-dose Chikungunya vaccine, IXCHIQ. The company is set to launch IXCHIQ in Europe in late 2024.

Zacks Equity Research

Should You Hold STERIS (STE) Stock Now? Here's What to Consider

by Zacks Equity Research

STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

Zacks Equity Research

Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues

by Zacks Equity Research

Henry Schein's (HSIC) revenue growth is supported by niche acquisitions and partnerships.

Zacks Equity Research

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.

Zacks Equity Research

Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial

by Zacks Equity Research

Neogen (NEOG) instills optimism among investors with its strategic progress and a string of product launches.

Zacks Equity Research

Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio

by Zacks Equity Research

Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.

Zacks Equity Research

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY

by Zacks Equity Research

Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.

Zacks Equity Research

Quest Diagnostics (DGX) to Expand in Canada With LifeLabs Buyout

by Zacks Equity Research

By integrating LifeLabs into its operations, Quest Diagnostics (DGX) aims to enhance the accessibility and quality of diagnostic services for Canadians.

Zacks Equity Research

Omnicell (OMCL) Banks on Product Launches, Global Growth

by Zacks Equity Research

Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.

Zacks Equity Research

Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs

by Zacks Equity Research

Thermo Fisher (TMO) has launched biobased solutions to help reduce the climate impact on the manufacturing of therapies.

Zacks Equity Research

Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab

by Zacks Equity Research

Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.

Zacks Equity Research

Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

by Zacks Equity Research

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

Zacks Equity Research

Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?

by Zacks Equity Research

Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.

Zacks Equity Research

National Vision (EYE) Gains Market Share Despite Macro Woes

by Zacks Equity Research

National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.

Zacks Equity Research

Thermo Fisher (TMO) Expands Central Lab Footprint in Kentucky

by Zacks Equity Research

Thermo Fisher (TMO) announces expansion of its central laboratory operations in Kentucky. The new space in Covington will be in addition to its existing central lab in Highland Heights.

Zacks Equity Research

Community Health (CYH) & Cost Plus Drugs Expand Collaboration

by Zacks Equity Research

Community Health (CYH) is now set to source drugs from the Cost Plus Drugs Marketplace under the new expanded partnership.

Zacks Equity Research

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?

by Zacks Equity Research

Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.

Zacks Equity Research

QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test

by Zacks Equity Research

QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.

Zacks Equity Research

Neogen (NEOG) Expands in Food Safety With Petrifilm Feeder Launch

by Zacks Equity Research

Neogen (NEOG) launches Petrifilm Automated Feeder, which allows automatic feeding and enumeration of up to 300 petrifilm plates in 33 minutes. The system improves the efficiency of food safety testing labs.

Zacks Equity Research

Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification

by Zacks Equity Research

Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.